title: Corrigendum to "Initial Experience With Tofacitinib in Clinical Practice: Treatment Patterns and Costs of Tofacitinib Administered as Monotherapy or in Combination With Conventional Synthetic DMARDs in 2 US Health Care Claims Databases" Clin Ther 38 (2016) 1451-63.
authors.affiliation: Pfizer Inc, New York, New York. Electronic address: James.Harnett@pfizer.com.
authors.forename: James
authors.initials: J
authors.lastname: Harnett
authors.affiliation: The University of Alabama, Birmingham, Alabama.
authors.forename: Jeffrey R
authors.initials: JR
authors.lastname: Curtis
authors.affiliation: Pfizer Inc, Groton, Connecticut.
authors.forename: Robert
authors.initials: R
authors.lastname: Gerber
authors.affiliation: Pfizer Inc, Groton, Connecticut.
authors.forename: David
authors.initials: D
authors.lastname: Gruben
authors.affiliation: Pfizer Inc, Collegeville, Pennsylvania.
authors.forename: Andrew
authors.initials: A
authors.lastname: Koenig